Accuray announces approval for Tomo C radiation therapy system in China

Accuray announced that the registration dossier for the CNNC-Accuray joint venture Tomo C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration, or NMPA. The new, made in China system, is the first joint venture product and represents an important achievement on behalf of cancer patients, many of whom will need treatment with radiotherapy at least once to cure their cancer, increase the chance of cure or relieve symptoms caused by cancer. The Tomo C platform features helical imaging and radiation delivery. With fully-integrated treatment planning, centralized data management and ultra-precise treatment delivery using patented beam-shaping technology, the system enables greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue.